Analysts at this broker write today that, "NVA237 (COPD) has been filed with Japanese regulators by Vectura's development partner Novartis. In addition Vectura has highlighted a respiratory-based copromotion agreement between Novartis and Japanese company Eisai, whereby the latter will help market both NVA237, and if approved, QVA 149, both which will yield royalty payments to Vectura. "The agreement is likely to maximise market penetration, and in turn potentially maximise royalty payments to the UK firm. We believe Vectura's business model remains strong, and we see the recent share price weakness as unwarranted, and a potential a buying opportunity for investors.""We maintain that the fundamentals for Vectura remain strong. Today's news indicates that the company's portfolio continues to progress, in the hands of partners Novartis, despite US regulatory delays. "We maintain our Buy recommendation and 120p target price, and continue to view the recent share price weakness as (i) unwarranted, and (ii) a buying opportunity."AB